Læknablaðið

Volume

Læknablaðið - 15.01.1999, Page 11

Læknablaðið - 15.01.1999, Page 11
LÆKNABLAÐIÐ 1999; 85 9 Meðferö viö lokastigsnýrnabilun á íslandi 1968-1997 Páll Ásmundsson, Runólfur Pálsson Ásmundssun P, Pálsson R Treatment of end-stage renal disease in Iceland 1968-1997 Læknablaðið 1999; 85: 9-24 Objective: Renal replacement therapy for end-stage renal disease (ESRD) has been provided in Iceland since 1968 when hemodialysis was begun. Kidney transplantation in Icelandic patients has been per- formed abroad since 1970 mainly in Copenhagen, Gothenburg and Boston. The purpose of this retro- spective study was to determine the changes in inci- dence, prevalence, and outcome of ESRD treatment during the period 1968-1997 and compare the results with other ESRD programs, mainly in the Nordic countries. Material and methods: Included in this study were all patients who began renal replacement therapy for ESRD during the study period and remained on therapy for at least six weeks. Data were obtained from the registry of ESRD, compiled by the Dialysis Service of the National University Hospital. The data were used to determine the annual incidence and prevalence of treated ESRD. Changes in parameters, such as age at the beginning of renal replacement therapy, gender distribution, causes of ESRD, treat- ment modalities, and survival were evaluated. An- nual mortality rate was calculated as deaths per 100 life-years. Comparison of means was done by the two sample t-test, survival was estimated by the Kap- lan-Meier method and survival differences were de- termined with the Mantel-Cox test. Results: A total of 201 patients began therapy for Frá blóöskilunardeild og lyflækningadeild Landspítalans. Fyrirspurnir, bréfaskipti: Páll Ásmundsson, blóðskilunar- deild Landspítalans, 101 Reykjavík; sími 560 1280, bréf- sími: 560 1287, netfang: pallas@rsp.is Lykilorö: lokastigsnýrnabilun, skilunarmeöferð, nýrna- ígræösla. ESRD during this 30 year period. The number of patients beginning renal replacement therapy in each of the three consecutive decades was 27, 59 and 115, respectively, which corresponds to 12.8, 25.1 and 44 per million population per year. The mean age rose throughout the study period and was 54.8 in the final decade. The prevalence per million population was 72 in 1977, 182 in 1987 and 356 in 1997. Diabetic nephropathy was not observed as a cause of ESRD until the last decade when it accounted for 12% of new patients. Hemodialysis was the sole dialysis modality until 1985. Peritoneal dialysis has since provided approximately one third of the dialysis treatment. The number of renal transplants was 13, 30 and 58 for each decade, respectively. At the end of 1997 there were 59 functioning allografts and of these 45 were from living donors. Patients with a functio- ning allograft were 70% of all ESRD patients at the end of 1997. Allografts came predominantly frorn cadaveric donors during the first two decades but living donors were 65% in the final decade. The five year survival of transplanted patients (81%) was markedly superior to that of dialyzed patients (16%). The annual mortality rate declined for the whole period, during the last decade it was 10.7 per 100 life-years for all patients, 27.9 for hemodialysis patients, 15.3 for peritoneal dialysis patients and 2.1 for transplanted patients. Death was mainly from cardiovascular causes and infections. Conclusions: There has been marked increase in the incidence and prevalence of treated ESRD in Iceland during the last 30 years. However, the incidence is low compared to the other Nordic countries, mainly as a result of low incidence of ESRD due to glomer- ulonephritis and diabetic nephropathy. Nearly half the ESRD population has received a renal transplant. Only Norway has a higher prevalence of transplanted patients among the ESRD pool. The percentage of living donor grafts among the transplanted patients is the highest the authors are aware of. Five year patient survival and renal allograft survival in Iceland were comparable to other countries. Keywords: end-stage renal failure, renal replacement therapy, kidney transplantation.
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Page 24
Page 25
Page 26
Page 27
Page 28
Page 29
Page 30
Page 31
Page 32
Page 33
Page 34
Page 35
Page 36
Page 37
Page 38
Page 39
Page 40
Page 41
Page 42
Page 43
Page 44
Page 45
Page 46
Page 47
Page 48
Page 49
Page 50
Page 51
Page 52
Page 53
Page 54
Page 55
Page 56
Page 57
Page 58
Page 59
Page 60
Page 61
Page 62
Page 63
Page 64
Page 65
Page 66
Page 67
Page 68
Page 69
Page 70
Page 71
Page 72
Page 73
Page 74
Page 75
Page 76
Page 77
Page 78
Page 79
Page 80
Page 81
Page 82
Page 83
Page 84
Page 85
Page 86
Page 87
Page 88
Page 89
Page 90
Page 91
Page 92
Page 93
Page 94
Page 95
Page 96
Page 97
Page 98
Page 99
Page 100
Page 101
Page 102
Page 103
Page 104
Page 105
Page 106
Page 107
Page 108
Page 109
Page 110
Page 111
Page 112
Page 113
Page 114
Page 115
Page 116

x

Læknablaðið

Direct Links

If you want to link to this newspaper/magazine, please use these links:

Link to this newspaper/magazine: Læknablaðið
https://timarit.is/publication/986

Link to this issue:

Link to this page:

Link to this article:

Please do not link directly to images or PDFs on Timarit.is as such URLs may change without warning. Please use the URLs provided above for linking to the website.